it is a single blind randomised control study which aims to study the effect of PEG3350 in
resolution of overt hepatic encephalopathy in patients of acute on chronic liver failure.
this will be compared with the standard of care in the management of hepatic encephalopathy.
Phase:
Phase 4
Details
Lead Sponsor:
Postgraduate Institute of Medical Education and Research